Milan J. Anadkat

First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation

Rizwan Romee, Sarah Cooley, Melissa M. Berrien-Elliott et al. · Blood · 2018 · 397 citations · Full text

Grading dermatologic adverse events of cancer treatments: The Common Terminology Criteria for Adverse Events Version 4.0

Alice P. Chen, Ann Setser, Milan J. Anadkat et al. · Journal of the American Academy of Dermatology · 2012 · 349 citations

Dermatologic Adverse Events, Cancer Treatments, Medicine +10

Trial of Spesolimab for Generalized Pustular Psoriasis

H. Bachelez, Siew Eng Choon, Slaheddine Marrakchi et al. · New England Journal of Medicine · 2021 · 317 citations · Full text

Cutaneous Toxic Effects Associated With Vemurafenib and Inhibition of the BRAF Pathway

Victor Huang, Donna M. Hepper, Milan J. Anadkat et al. · Archives of Dermatology · 2012 · 101 citations

Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial

Akimichi Morita, Bruce Strober, A. David Burden et al. · The Lancet · 2023 · 100 citations · Full text

Effisayil 2, Medicine, Clinical Dermatology +4